Description: PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Home Page: polynovo.com
320 Lorimer Street
Port Melbourne,
VIC
3207
Australia
Phone:
61 3 8681 4050
Officers
| Name | Title |
|---|---|
| Mr. Jan-Marcel Gielen C.A. | CFO & Company Sec. |
| Dr. David McQuillan Ph.D. | Chief Technical & Scientific Officer |
| Mr. Swami Raote BPHARM, M.B.A. | CEO & Director |
| Mr. Ahmed Hassan | Director of Operations |
| Ms. Teena Chadha | APAC Marketing & Distributor Mang. |
| Ms. Monica Benyk | HR Mang. |
| Dr. Tim Moore | Principal Scientist |
| Mr. Edward Graubart | Sr. VP of Sales & Marketing (Americas) |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 30.03 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 76.436 |
| Price-to-Sales TTM: | 21.2746 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 152 |